Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Repurposing a novel anti-cancer RXR agonist to attenuate murine acute GVHD and maintain graft-versus-leukemia responses.

Autor: Thangavelu G; Division of Blood and Marrow Transplantation, Department of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis, MN., Wang C; Evergrande Center for Immunologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA., Loschi M; Division of Blood and Marrow Transplantation, Department of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis, MN., Saha A; Division of Blood and Marrow Transplantation, Department of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis, MN., Osborn MJ; Division of Blood and Marrow Transplantation, Department of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis, MN., Furlan SN; Ben Towne Center for Childhood Cancer Research, Seattle Children's Research Institute, University of Washington, Seattle, WA., Aoyama K; Division of Blood and Marrow Transplantation, Department of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis, MN., McDonald-Hyman C; Division of Blood and Marrow Transplantation, Department of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis, MN., Aguilar EG; Division of Blood and Marrow Transplantation, Department of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis, MN., Janesick AS; Department of Developmental and Cell Biology, University of California, Irvine, Irvine, CA., Chandraratna RA; Io Therapeutics, Santa Ana, CA., Refaeli Y; Department of Dermatology, University of Colorado, Aurora, CO., Panoskaltsis-Mortari A; Division of Blood and Marrow Transplantation, Department of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis, MN., MacDonald KP; Department of Immunology, Queensland Institute of Medical Research (QIMR), University of Queensland, Brisbane, QLD, Australia., Hill GR; Clinical Research Division and.; Division of Medical Oncology, Fred Hutchinson Cancer Research Center, Seattle, WA., Zeiser R; Department of Internal Medicine I, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany., Maillard I; Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA., Serody JS; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC., Murphy WJ; Department of Dermatology, School of Medicine, University of California, Davis, Sacramento, CA., Munn DH; Georgia Cancer Center, Augusta University, Augusta, GA., Blumberg B; Department of Developmental and Cell Biology, University of California, Irvine, Irvine, CA., Brown C; Division of Transplantation Immunology and Mucosal Biology, King's College London, London, United Kingdom., Kuchroo V; Evergrande Center for Immunologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA., Kean LS; Division of Pediatric Hematology/Oncology, Boston Children's Hospital, Dana-Farber Cancer Institute, Boston, MA; and., Hippen KL; Division of Blood and Marrow Transplantation, Department of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis, MN., Noelle RJ; Department of Microbiology and Immunology, Norris Cotton Cancer Center, Geisel School of Medicine, Dartmouth College, Lebanon, NH., Blazar BR; Division of Blood and Marrow Transplantation, Department of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis, MN.

Publikováno v: Blood [Blood] 2021 Feb 25; Vol. 137 (8), pp. 1090-1103.